JF

20

Sep2016

Ontario Releases Updated Guidelines for Drug Submission and Evaluation 2016

To help drug manufacturers prepare drug submissions, the Ministry of Health and Long-Term Care has updated its Ontario Guidelines for Drug Submission and Evaluation (Guidelines). The Guidelines take effect on October 6, 2016. All submissions received on or after this date must comply. The updated Guidelines reflect current regulatory and policy requirements ... Read More

13

Sep2016

Feedback on Proposed Revisions to Patient Input Template for CDR and pCODR

CADTH is inviting stakeholder comments on proposed changes to the patient input template for the CADTH Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR). Patient input is used by CADTH review teams and by the expert committees of the CDR and pCODR programs: the CADTH Canadian ... Read More

08

Sep2016

The pCPA: Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2016: 40 negotiations are currently underway with 10 files added since the last update of July 31, 2016: Cotellic (cobimetinib): used to treat metastatic melanoma Fabrazyme (agalsidase beta): used to treat ... Read More

26

Aug2016

Registration is Underway for the CAHR Market Access 201 Course

The Canadian Association for Healthcare Reimbursement (CAHR) is hosting Market Access 201-Fundamentals of Reimbursement in Canada. This one-day training course is a continuation of Market Access 101 and offers a deeper dive into Market Access strategies. The program will be emceed by Dr. Jeffery Hoch from the Department of ... Read More

26

Aug2016

PDCI Market Access WEBINAR ‒ Possible 2nd Session September 8, 2016 (date tentative)

Information Session on the PMPRB Guidelines Modernization Discussion Paper On August 23rd, 2016, PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, held a free “Information Session on the PMPRB Guidelines Modernization Discussion Paper”. This came shortly after the PMPRB recently releasing its long awaited consultation paper “PMPRB ... Read More

19

Aug2016

PMPRB 2015 Annual Report Released

2015 Annual Report Released  Earlier today, the Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, released its Annual Report for the year ended December 31, 2015. The Annual Report is an extensive document that reviews all of the PMPRB’s major activities, analyses of ... Read More

17

Aug2016

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2016: 32 negotiations are currently underway with 2 files added since the last update of June 30, 2016: Avastin (bevacizumab): used to treat genitourinary platinum-resistant ovarian cancer Opdivo (nivolumab): used to ... Read More

29

Jul2016

SAVE THE DATE

PDCI’s PMPRB Guidelines Modernization Webinar Session On June 24, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”.  The paper, the initial phase of a three-part Guideline modernization process, asserts that PMPRB’s current framework is outdated and seeks feedback on a wide range ... Read More

12

Jul2016

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2016: 33 negotiations are currently underway with 8 files (including 2 biosimilars) added since the last update of May 31, 2016: Abilify (aripiprazole): used for the treatment of schizophrenia and related ... Read More

04

Jul2016

PMPRB Guideline Modernization – PDCI to hold Industry Information Sessions in August / September

On June 24, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”.  The paper, the initial phase of a three-part Guideline modernization process, asserts that PMPRB’s current framework is outdated and seeks feedback on a wide range of issues that will inform ... Read More